• Figure 1.

    Proposed pathogenesis of IgA nephropathy (IgAN) and potential therapeutic targets.

  • 1.

    Floege J, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 95:268280.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Rovin BH, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 95:281295.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Goodship TH, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2017; 91:539551.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

KDIGO Quo Vadis: Updating Guidance for the Management and Treatment of Glomerulonephritis

Jürgen Floege Jürgen Floege, MD, PhD, is director of the Division of Nephrology, Rheinisch-Westfälische Technische Hochschule Aachen University, Aachen, Germany. Brad H. Rovin, MD, is director of the Division of Nephrology, Wexner Medical Center at Ohio State University, Columbus, USA.

Search for other papers by Jürgen Floege in
Current site
Google Scholar
PubMed
Close
and
Brad H. Rovin Jürgen Floege, MD, PhD, is director of the Division of Nephrology, Rheinisch-Westfälische Technische Hochschule Aachen University, Aachen, Germany. Brad H. Rovin, MD, is director of the Division of Nephrology, Wexner Medical Center at Ohio State University, Columbus, USA.

Search for other papers by Brad H. Rovin in
Current site
Google Scholar
PubMed
Close
Restricted access
Save